Article Text

Download PDFPDF
82 Identification of neoantigens from non-primary tumor tissue in patients with recurrent ovarian cancer by sequencing and subsequent HLA ligand mass spectrometry
  1. R O’Cearbhaill1,
  2. M Klatt2,
  3. SS Mun2,
  4. T Korontsvit2,
  5. N Socci3,
  6. S Guzman2,
  7. M Mattar4,
  8. O Zivanovic5 and
  9. T Dao2
  1. 1Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, Medicine, New York, USA
  2. 2Sloan Kettering Institute, Molecular Pharmacology, New York, USA
  3. 3Memorial Sloan Kettering Cancer Center, Bioinformatics Core, New York, USA
  4. 4Sloan Kettering Institute, Clinical Research, New York, USA
  5. 5Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, Gynecologic Surgical Oncology, New York, USA


Objectives Adoptive transfer of autologous Tcells specifically targeting neoepitopes derived from tumor mutations has achieved responses in melanoma and other cancers. We sought to identify ovarian cancer neoepitopes.

Methods We collected tumor, blood and ascites specimens from ovarian cancer patients. We combined mass spectrometry analysis of MHC class1 peptidomes with parallel sequencing of whole exome and RNA of cancer cells, to identify neoepitopes. Missense mutations were identified by whole exome sequencing and epitopes confirmed by mass spectrometry from ascites. We selected peptides predicted to have high binding affinity to HLA-A*02:01, for in vitro Tcell priming. We first validated the immunogenicity of these peptides for priming Tcells with synthesized peptides in healthy HLA-A*02:01+ donors.

Results 32 missense mutations were identified in patient’s ascites. 7 epitopes were confirmed by mass spectroscopy; 5 were predicted to have high binding affinity to HLA-A*02:01. 3/5 epitopes induced peptide-specific Tcell responses not cross-reactive with native sequences. However, these 3 peptides failed to induce autologous peptide-specific Tcell response in TILs to patient‘s ascites, nor to autologous tumor cells, suggesting immunosuppression. Interestingly, when autologous tumor cells were pre-treated with IFN-gamma, Tcell responses against tumor cells were observed.

Conclusions We demonstrated effective T cell responses against tumor neoantigens, is not only dependent on stimulation of Tcells, but also on efficient epitope processing and presentation on cell surface. While efforts have been focused on activation of Tcell responses, such as immune checkpoint blockade, our study suggests that strategies to modulate tumor cells to efficiently present neoepitopes should be considered for successful immunotherapy against neoantigens.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.